在近期举行的新药上市申请前沟通会议上，Gyre Therapeutics与中国国家药品监督管理局药品审评中心就海通酮（Hydronidone）的注册路径达成重要共识。根据会议结果，该药物已明确符合中国附条件批准上市的标准，并同时获得优先审评资格认定。
这一突破性进展为海通酮在中国市场的商业化进程奠定了坚实基础。附条件批准机制将显著加速创新药物惠及患者的周期，而优先审评资格则进一步确保了审评资源的高效配置。两项政策红利的叠加，凸显出该药物在应对未满足临床需求方面的突出价值。
Gyre Therapeutics表示，公司将严格遵循药监局要求，有序推进后续申报工作。此次 alignment 不仅体现了中国监管机构对创新药研发的支持力度，也展现出Gyre Therapeutics在全球肝病治疗领域的技术领先地位。行业观察人士指出，这一进展有望为同类创新药物的审评路径提供重要参考。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.